Buscar
Agenus Inc
AGENAñadir a la lista de seguimiento
3.580USD
0.0000.00%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
149.08MCap. mercado
1.73P/E TTM
Más Datos de Agenus Inc Compañía
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Información de Agenus Inc
Símbolo de cotizaciónAGEN
Nombre de la empresaAgenus Inc
Fecha de salida a bolsaFeb 04, 2000
Director ejecutivoArmen (Garo H)
Número de empleados316
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 04
Dirección3 Forbes Rd
CiudadLEXINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02421-7305
Teléfono17816744400
Sitio Webhttps://agenusbio.com/
Símbolo de cotizaciónAGEN
Fecha de salida a bolsaFeb 04, 2000
Director ejecutivoArmen (Garo H)
Ejecutivos de Agenus Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
39.00K
+23.66%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
39.00K
+23.66%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Non-cash royalty revenue
108.59M
95.09%
Pre-commercial product revenue
4.24M
3.71%
Other services
1.04M
0.91%
Clinical product revenue
334.00K
0.29%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
113.16M
99.09%
Rest of World
1.04M
0.91%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Non-cash royalty revenue
108.59M
95.09%
Pre-commercial product revenue
4.24M
3.71%
Other services
1.04M
0.91%
Clinical product revenue
334.00K
0.29%
Estadísticas de accionistas
Actualizado: mié., 13 de may
Actualizado: mié., 13 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Zydus Lifesciences Ltd
5.12%
Vanguard Capital Management, LLC
3.46%
Vanguard Portfolio Management, LLC
2.87%
Invus Public Equities Advisors, LLC
2.56%
Renaissance Technologies LLC
1.31%
Otro
84.69%
Accionistas
Accionistas
Proporción
Zydus Lifesciences Ltd
5.12%
Vanguard Capital Management, LLC
3.46%
Vanguard Portfolio Management, LLC
2.87%
Invus Public Equities Advisors, LLC
2.56%
Renaissance Technologies LLC
1.31%
Otro
84.69%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
13.72%
Investment Advisor/Hedge Fund
5.42%
Hedge Fund
5.15%
Corporation
5.14%
Individual Investor
1.56%
Research Firm
1.12%
Pension Fund
0.91%
Otro
66.99%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
275
10.91M
26.27%
-968.40K
2025Q4
304
9.95M
37.38%
--
2025Q3
332
9.95M
41.39%
+217.92K
2025Q2
334
9.73M
47.54%
+407.61K
2025Q1
334
9.33M
45.75%
-2.82M
2024Q4
341
8.45M
52.98%
-249.79K
2024Q3
351
8.70M
54.68%
-447.45K
2024Q2
347
9.21M
64.12%
-1.91M
2024Q1
356
10.69M
65.28%
-2.98M
2023Q4
374
11.90M
61.88%
+645.94K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Zydus Lifesciences Ltd
2.13M
5.56%
+2.13M
--
Jan 15, 2026
Invus Public Equities Advisors, LLC
1.06M
2.77%
--
--
Dec 31, 2025
Renaissance Technologies LLC
543.55K
1.42%
+477.35K
+721.07%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
485.30K
1.26%
+16.52K
+3.52%
Dec 31, 2025
Citadel Advisors LLC
423.24K
1.1%
+423.24K
--
Dec 31, 2025
Armen (Garo H.)
394.77K
1.03%
+8.98K
+2.33%
Mar 20, 2026
Geode Capital Management, L.L.C.
372.75K
0.97%
+25.76K
+7.42%
Dec 31, 2025
Wellington Management Company, LLP
290.65K
0.76%
--
--
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0%
iShares Russell 3000 ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Fidelity Enhanced Small Cap ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Schwab U.S. Small-Cap ETF
Proporción0%
SPDR Portfolio MSCI Global Stock Market ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
